A2A Pharmaceuticals, Inc., 10% Owner at Biomea Fusion, Inc. (BMEA), sold 69,316 shares at $11.21 ($777K) on 2022-07-21, disclosed to the SEC on 2022-07-25.
Open-market sale of $777k BMEA by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.21 | 34,658 | $389K | 50.0% |
| 2 | $11.21 | 34,658 | $389K | 50.0% |
| Total | $11.21 avg | 69,316 | $777K | 100% |
| Filing → |
| BMEA | SELL | 2023-05-10 | $8.6M | — | Filing → |
| BMEA | SELL | 2023-04-26 | $5.8M | — | Filing → |
| BMEA | SELL | 2023-04-06 | $6.3M | — | Filing → |